Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06842823 · ClinicalTrials.gov registry record · Phase 3
A Study of Navenibart in Participants With Hereditary Angioedema
A Phase 3 study of Hereditary Angioedema (HAE), sponsored by Astria Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 145
- Enrollment target
- 20
- Study locations
NCT06842823 is a Phase 3 study of Hereditary Angioedema (HAE) that is actively recruiting participants, run by Astria Therapeutics. The registered enrollment target is 145 participants, above the 47-participant average among 7 other Hereditary Angioedema (HAE) trials with a reported enrollment target (209% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT06842823, a Phase 3 study of Hereditary Angioedema (HAE), is actively recruiting participants, sponsored by Astria Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 145 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of subcutaneous administration of navenibart in adult and adolescent participants with type 1 or type 2 hereditary angioedema (HAE). The goal of this clinical trial is to evaluate the efficacy and safety of navenibart compared to placebo in preventing HAE attacks in participants with HAE.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG navenibart
Study Locations (20)
California
- Site 26 - San Diego
- Site 14 - San Diego
- Site 4 - Santa Monica
- Site 1 - Walnut Creek
Colorado
- Site 8 - Centennial
- Site 11 - Colorado Springs
Florida
- Site 25 - Tampa
- Site 69 - Weston
Ohio
- Site 7 - Cincinnati
- Site 12 - Toledo
Alabama
- Site 9 - Birmingham
Arizona
- Site 2 - Scottsdale
Arkansas
- Site 3 - Little Rock
Kansas
- Site 43 - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2025-03-20 |
| Est. Completion | 2027-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06842823
The ClinicalTrials.gov registry entry for NCT06842823 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 47-participant average among 7 other Hereditary Angioedema (HAE) trials with a reported enrollment target (209% higher). The listed sponsor is Astria Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hereditary Angioedema (HAE) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06842823 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT06842823 about?
NCT06842823 is a clinical study titled "A Study of Navenibart in Participants With Hereditary Angioedema". This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of subcutaneous administration of navenibart in adult and adolescent participants with type 1 or type 2 hereditary angioedema (HAE). The goal of this clinical trial is to eva...
What is the current status of trial NCT06842823?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 145 participants. The study started on 2025-03-20. Estimated completion is 2027-09.
What conditions does trial NCT06842823 study?
This clinical trial studies the following conditions: Hereditary Angioedema (HAE).
What interventions are being tested in trial NCT06842823?
The interventions under investigation include: Placebo (DRUG), navenibart (DRUG).
Who is sponsoring clinical trial NCT06842823?
This trial is sponsored by Astria Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06842823 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Angioedema (HAE)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
RECRUITING · Phase 3
-
Donidalorsen Treatment in Children With Hereditary Angioedema
RECRUITING · Phase 3
-
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema
COMPLETED · Phase 3
-
Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients
RECRUITING · Phase 1
-
A Phase 2 in Adult Subjects With Hereditary Angioedema
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.